Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296099 · ClinicalTrials.gov registry record · Phase 4
Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence
A Phase 4 study of Urinary Incontinence, Stress, sponsored by TriHealth.
- Completed
- Registry status
- Phase 4
- Development phase
- 114
- Enrollment target
- 1
- Study location
NCT02296099 is a Phase 4 study of Urinary Incontinence, Stress that has completed, run by TriHealth. The registered enrollment target is 114 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02296099, a Phase 4 study of Urinary Incontinence, Stress, has completed, sponsored by TriHealth.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 114 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine if the administration of liposomal bupivacaine at the completion of a suburethral sling procedure will result in decreased postoperative pain compared to no injection.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG liposomal bupivacaine
Study Locations (1)
Ohio
- Cincinnati Urogynecology Associates - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2014-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296099
The ClinicalTrials.gov registry entry for NCT02296099 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TriHealth, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Incontinence, Stress appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02296099 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02296099 about?
NCT02296099 is a clinical study titled "Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence". The purpose of the study is to determine if the administration of liposomal bupivacaine at the completion of a suburethral sling procedure will result in decreased postoperative pain compared to no injection.
What is the current status of trial NCT02296099?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 114 participants. The study started on 2014-11. Estimated completion is 2016-08.
What conditions does trial NCT02296099 study?
This clinical trial studies the following conditions: Urinary Incontinence, Stress.
What interventions are being tested in trial NCT02296099?
The interventions under investigation include: Placebo (DRUG), liposomal bupivacaine (DRUG).
Who is sponsoring clinical trial NCT02296099?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02296099 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence, Stress
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.